Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • S&P 500

    5,252.15
    +3.66 (+0.07%)
     
  • Dow

    39,736.68
    -23.40 (-0.06%)
     
  • Nasdaq

    16,394.43
    -5.09 (-0.03%)
     
  • Bitcoin USD

    71,386.20
    +1,648.02 (+2.36%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,972.34
    +40.36 (+0.51%)
     
  • Gold

    2,234.70
    +22.00 (+0.99%)
     
  • Crude Oil

    82.71
    +1.36 (+1.67%)
     
  • 10-Yr Bond

    4.1940
    -0.0020 (-0.05%)
     
  • Nikkei

    40,168.07
    -594.66 (-1.46%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE Bursa Malaysia

    1,530.60
    -7.82 (-0.51%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Gilead Sciences Signs $2 Billion Partnership with Arcus Biosciences

Gilead Sciences Signs $2 Billion Partnership with Arcus Biosciences

Gilead Sciences (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have signed a 10-year agreement to co-develop and co-commercialize the next-generation cancer therapeutics in Arcus' pipeline. The agreement also gives Gilead an equity position in the small-cap, clinical-stage biotech company. Shares of Gilead inched up 0.7% Wednesday on the news, but investors apparently thought Arcus didn't drive a hard enough bargain -- its stock fell 13% to $29.